FY27 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
FDA OFFICE OF ACQ GRANT SVCS
Contract Value
Not provided
Codes & Classification
Solicitation Number
FDABAA-27-00123
NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Classification Code
AJ11
Additional Details
Documents4
The U.S. Food and Drug Administration (FDA), under the Department of Health and Human Services, has issued a Broad Agency Announcement (BAA) for Fiscal Year 2027, titled "FY27 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science" (Procurement Identifier: FDABAA-27-00123). This special notice seeks proposals for both basic and applied research and development projects that will advance regulatory science and innovation in support of the FDA’s mission to protect and promote public health.
The scope of this BAA encompasses a wide range of scientific research areas and sub-areas, as detailed within the full announcement. The FDA is particularly interested in projects that contribute to the advancement of scientific knowledge and address regulatory science challenges relevant to its core responsibilities. The intended outcome is to fund extramural research that directly supports the FDA’s ability to evaluate and regulate products efficiently and effectively, thereby enhancing the agency’s capacity to safeguard the nation’s health.
Key requirements for this opportunity include the submission of research proposals that align with the FDA’s identified areas of interest. While the Product Service Code (PSC) "AJ11" (General Science and Technology R&D Services; Health) is specified, the FDA clarifies that proposals are not limited to this code alone, allowing for a broader range of scientific disciplines and approaches. The applicable North American Industry Classification System (NAICS) code is 541714, which covers Research and Development in Biotechnology (except Nanobiotechnology), as per the 2022 NAICS version.
This procurement is classified as a special notice and is not set aside for any specific group; there are no set-aside requirements, making it open to all eligible entities capable of fulfilling the research objectives. The contracting activity is managed by the FDA Office of Acquisition and Grant Services, with Ian Weiss serving as the primary point of contact ([email protected], 301-796-5728).
Interested parties should note the following key dates: the proposal due date has been updated to January 22, 2027, at 5:00 pm, and the special notice archive date is set for September 30, 2027. The opportunity remains active and is accessible via the official SAM.gov portal (Opportunity ID: 85dacc8ad6aa4cd59ae08f37a9f63355), where additional attachments and details can be found.
Contractors considering this opportunity should ensure their research capabilities align with the FDA’s regulatory science priorities and be prepared to deliver innovative, scientifically rigorous solutions that can inform and enhance the agency’s regulatory decision-making processes. This BAA represents a significant opportunity for organizations specializing in biotechnology research and development to contribute to the advancement of public health through regulatory science.